web analytics
September 2, 2014 / 7 Elul, 5774
At a Glance

Posts Tagged ‘medicine’

Israeli Treatment for Gaucher Disease Approved in Canada

Monday, June 2nd, 2014

Canada has approved Elelyso, a new Israeli treatment for Type 1 Gaucher disease. The medication received kosher certification from the Orthodox Union, according to Pfizer, which distributes the drug in the United States.

Gaucher disease is an inherited disease in which the body does not store lipids correctly. This results in a buildup of the fatty substances in cells, certain organs and sometimes in the bone tissue, causing damage to organs such as the spleen, liver and brain.

Elelyso (taliglucerase alfa) is a long-term enzyme replacement therapy produced by Protalix Biotherapeutics Inc., which treats the disease in both adults and children.”

Elelyso was approved by the U.S. FDA on May 1, 2012 and received marketing authorization from the Israeli Ministry of Health on September 12, 2012. It is also approved in a number of other countries, including Brazil and Uruguay.

“With the Canadian approval of Elelyso, the drug is now approved for patients in more than ten countries across the globe,” said Protalix SVP product development Dr. Einat Brill Almon.

“This validates the ability and safety of ProCellEx, our manufacturing platform technology, which we are currently using to develop additional enzyme replacement therapies.”

Common Blood Pressure Drug Prevents Post-TBI Epilepsy

Wednesday, April 23rd, 2014

Israeli researchers working with an international team have discovered that a common blood pressure medication can prevent epilepsy from developing after a traumatic brain injury.

The discovery is described in an article published in the current issue of the Annals of Neurology.

Physiology and Neurobiology Professor Alon Friedman works at the Zlotowski Center for Neuroscience at Ben Gurion University of the Negev in southern Israel. He worked with Daniela Kaufer, UC Berkeley Associate Professor of Integrative Biology at the Helen Wills Neuroscience Institute and Uwe Heinemann of Charite-University Medicine in Germany on the 10-year study.

In 60 percent of the experimental rats tested, the medication – losartan (Cozaar) – prevented the development of seizures following injury in which 100 percent of controls developed seizures. Of the 40 percent that did develop seizures, the researchers said the rats averaged only one quarter of the number of seizures typical for untreated subjects.

Medication administered for three weeks following injury was sufficient to prevent most cases of epilepsy in normal subjects in the subsequent months, the researchers said.

“This is the first-ever approach in which epilepsy development is stopped,” Friedman explained, “as opposed to common drugs that try to prevent seizures once epilepsy develops… so we are excited about the new approach.”

The researcher added that the study provided a new way to potentially prevent epilepsy in patients after brain injuries occurred, and once they had already developed an abnormal blood-brain barrier. The best news, he said, is that the drug stops the epilepsy from starting, rather than simply suppresses the symptoms.

Teva Wins FDA Approval for Leukemia Drug

Thursday, February 13th, 2014

The U.S. Food and Drug Administration (FDA) has granted Israeli-based Teva Pharmaceuticals full approval for Synribo, a drug that is injected for adults with a with chronic phase or accelerated phase of myeloid leukemia.

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is one of four main types of leukemia and is a cancer of the blood and bone marrow.

The FDA had given initial approval for the drug in October 2012 but said Teva had to provide additional clinical trial data before it could bring the drug to market.

“With this approval, based on the final analysis of two Phase II trials that evaluated efficacy and tolerability data of Synribo, we believe healthcare providers can be even more confident in the clinical profile of this important medicine, said Teva president and CEO global specialty medicines Rob Koremans.

No More Lies, Sec. Kerry, There Is No ‘Existential Threat to Israel’

Sunday, January 26th, 2014

Is Secretary of State, John Kerry correct, or incorrect, when exhorting “the demographic time bomb” to scare Israel into a retreat from geography (Judea and Samaria), in order to, supposedly, secure demography?  According to Kerry, “There is an existential threat to Israel…. I am referring to the demographic dynamic that makes it impossible for Israel to preserve its future as a democratic, Jewish state without resolving the Israeli-Palestinian conflict in a two-state solution.”

Are Jews doomed to become a minority in the combined area of Judea, Samaria and the pre-1967 Israel?

According to the 2013 CIA World Factbook,  Judea and Samaria Arabs  experienced a dramatic decline in fertility rate (the average number of births per woman): from five births in 2000 to 2.91 in 2013.  On the other hand, in 2014, Israel’s Central Bureau of Statistics documents a 3.04 Jewish fertility rate and 3.42 when both Jewish spouses are Israeli-born.

“A new Palestinian generation opts for fewer children is the title of an article by Rasha Abou Jalal, a Gaza journalist:  While Islam calls for believers to bear many children and prohibits the use of birth control, new Palestinian generations are defying tradition and leaning toward limiting the number of children they have…. The new generation takes into consideration various economic and cultural factors before deciding to have children.  The idea of limiting childbearing has, therefore, garnered more supporters than before…. The more Palestinians become aware and rational, the less they will procreate, as they pursue a level of education and knowledge that suits them and increases their chances of having a better life….

The Westernization of Muslim demographic trends, from Iran (1.8 births per woman), through Saudi Arabia (2.3), Syria and Egypt (2.9) and North Africa (1.8) has also characterized Muslim women in Judea, Samaria, Gaza and pre-1967 Israel. The unprecedented decline in Muslim fertility has been driven by modernity: accelerated women’s rights, urbanization, education, career mentality and family planning (72% of 15-49 year old married Palestinian women prefer to avoid pregnancy).  Thus, contemporary young Muslim women are reluctant to get married at the age of fifteen and start reproducing at the age of sixteen.  They tend to postpone marriage until after the age of 20 and prefer limited reproduction.

On the other hand, in 2014, the Israeli Jewish fertility rate (three births per woman and trending upwards) is higher than in any Arab country, other than Yemen, Iraq and Jordan.  Jewish demography has been enhanced by a high level of optimism, patriotism, communal responsibility and attachment to roots among religious and secular, hawks and doves, conservative and liberal Israelis, bolstered by economic progress. While the annual number of Arab births – west of the Jordan River – has stabilized since 1995, the annual number of Jewish births has surged from 80,000 in 1995 to about 132,000 in 2013 – a 65% increase!  This dramatic leap occurred despite declining fertility among ultra-orthodox Jews, but due to the substantial rise of secular Jewish fertility.  In 1995 there were 2.3 Jewish births per one Arab birth in Israel; in 2014 – 3.3 births.  In 1995, the number of Jewish births constituted 69% of total Israeli births; in 2014 – 77% and rising.

In 2014, there is a robust 66% Jewish majority in the combined area of Judea, Samaria and pre-1967 Israel – compared with a 9% and 39% in 1900 and 1947 – benefitting from a tailwind of fertility and net-immigration.  This contrasts with declining Arab fertility and annual Arab net-emigration (in 2014, 20,000 from Judea and Samaria).  In 2014, Israel’s Jewish population has reached 6.5 million people, next to 1.7 million Israeli Arabs and 1.7 million Judean and Samarian Arabs – one million less than the number claimed by the Palestinian Authority.  The misrepresentation was conceived in the late 1990s, in response to the arrival of one million Soviet Jews to Israel.  It consists of overseas residents, overseas births, by double-counting Jerusalem Arabs as Israeli Arabs (by Israel) and West Bankers (by the Palestinian Authority), etc..

Government Panel Wants to Fund Abortions

Monday, December 30th, 2013

The government will actively promote abortions by funding them for women between ages 20 and 33 if a proposal by a Health Ministry committee is accepted.

Israel’s”basket” of drugs and medical treatment gives hefty discounts for citizens, and the government adds “goodies” to the basket each year. The committee that came up with this coming year’s basket recommends that health funds cover abortions for women in the age bracket even if they have no medical reason to terminate a pregnancy.

Drugs for ADD/ADHD and alcohol addiction were not included in the recommendations for this year’s basket, but approval was suggested for new drugs for cancer treatment, AIDS and epilepsy.

Israeli Researcher: Chewing Gum Cause of Migraines in Teens

Thursday, December 19th, 2013

Teenagers who love chewing, smacking and bubble-popping gum may be giving themselves a headache, according to research by Dr. Nathan Watemberg of Tel Aviv University-affiliated Meir Medical Center. His findings, published in Pediatric Neurology, could help treat countless cases of migraine and tension headaches in adolescents without the need for additional testing or medication.

Dr. Watemberg noticed at Meir’s Child Neurology Unit and clinics that many patients who reported headaches were daily gum chewers. Teenage girl patients were particularly avid chewers — a finding supported by previous dental studies.

He asked 30 patients between six and 19 years old who had chronic migraine or tension headaches and chewed gum daily to quit chewing gum for one month. After a month without gum, 19 of the 30 patients reported that their headaches went away entirely and seven reported a decrease in the frequency and intensity of headaches. To test the results, 26 of them agreed to resume gum chewing for two weeks. All of them reported a return of their symptoms within days.

“Out of our 30 patients, 26 reported significant improvement, and 19 had complete headache resolution,” said Dr. Watemberg. “Twenty of the improved patients later agreed to go back to chewing gum, and all of them reported an immediate relapse of symptoms.”

Aspartame, a common ingredient found in sugarless gum, has long been suspected of causing neurological damage. Prior to the European Food Safety Authority recently declaring the artificial sweetener as safe, studies have suggested it may provoke headaches in susceptible individuals. However, the Israeli researchers believe that the amount of aspartame released in gum is likely to be low because the flavor of gum is typically lost after the first few minutes of chewing. Rather, they believe the likely reason for the link between gum-chewing and headaches is the stress on the TMJ.

“Every doctor knows that overuse of the TMJ will cause headaches,” Dr. Watemberg said in a statement. “I believe this is what’s happening when children and teenagers chew gum excessively.”

A possible explanation for the association that exists between chewing gum and headaches is the stress placed on the temporomandibular joint (TMJ), where the skull and jaw meet. Chewing gum causes unnecessary wear and tear of the cartilage that acts as a shock absorbent in the jaw joints, which can lead to pain and discomfort, Dr. Ben Kim, who is not not involved in the study. told the website Medical Daily.

Gum chewers use eight different facial expression when they chew. If used excessively, this can create chronic tightness in two of these muscles that are located near an individual’s temples. Therefore, the nerves that are on this area of the head feel extreme pressure, which can lead to chronic, reoccurring headaches.

Israeli Developer of Swallowable Camera Bought for $860 Million

Monday, December 9th, 2013

An Irish company will purchase Given Imaging Ltd., an Israeli firm that developed a swallowable camera to diagnose problems in the digestive tract.

Covidien Plc agreed to acquire Given Imaging from shareholders of IDB Holding Corp. Ltd. for about $860 million, it was reported Sunday. Given Imaging is the inventor of the PillCam, a swallowed optical endoscopy technology.

Covidien acquired three other Israeli medical device companies, all in 2012.

IDB subsidiaries Discount Investment Corp., Elron Electronic Industries and Rafael Development Corp. hold stakes in Given Imaging. The three companies were set to approve the deal on Sunday, which also must be approved by shareholders of Given Imaging.

Printed from: http://www.jewishpress.com/news/breaking-news/israeli-developer-of-swallowable-camera-bought-for-860-million/2013/12/09/

Scan this QR code to visit this page online: